A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease, Ester in t Groen, EMEA Therapeutic Area head, Haematology, at Johnson & Johnson, stated in a news release.1 Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families. To view or add a comment, sign in 7,152 followers
But heres the question: Is HHVB GLP-1 really effectiveor is it another well-disguised online scam
Get The Brighter Side of News' newsletter.
It does it by breaking down sugar stored in the liver (glycogen) and making glucose from non-carbohydrate sources during fasting
MTHFR Gene C677T Polymorphism in Autism Spectrum Disorders
The medication is prescribed for adults with a BMI similar to Semaglutide/GLP-1 users